Table 2.
Matching scheme for the second cohort of breast cancer samples pre- and post-chemotherapy. *
| Group Demographics Clinical Status |
Pre-Chemo | Percentage (%) | Post-Chemo | Percentage (%) |
|---|---|---|---|---|
| Age < 55, Race = white ER+ PR+ HER2+ |
15 | 2.18 | 1 | 2.22 |
| Age < 55, Race = white ER+PR-/ER-PR+/ER-PR-HER2- |
89 | 12.90 | 5 | 11.11 |
| Age < 55, Race = white ER+PR-/ER-PR+/ER-PR-HER2+ |
21 | 3.04 | 2 | 4.44 |
| Age < 55, Race = white ER-PR-HER2- |
46 | 6.67 | 7 | 15.56 |
| Age < 55, Race = non-white ER+PR+HER2+ |
22 | 3.19 | 1 | 2.22 |
| Age < 55, Race = non-white ER+PR-/ER-PR+/ER-PR-HER2- |
52 | 7.53 | 6 | 13.33 |
| Age < 55, Race = non-white ER+PR-/ER-PR+/ER-PR-HER2+ |
35 | 5.07 | 4 | 8.89 |
| Age < 55, Race = non-white ER-PR-HER2- |
48 | 6.96 | 4 | 8.89 |
| Age > 55, Race = white ER+PR+HER2+ |
31 | 4.49 | 0 | 0 |
| Age > 55, Race = white ER+PR-/ER-PR+/ER-PR-HER2- |
94 | 13.62 | 6 | 13.33 |
| Age > 55, Race = white ER+PR-/ER-PR+/ER-PR-HER2+ |
30 | 4.35 | 3 | 6.66 |
| Age > 55, Race = white ER-PR-HER2- |
55 | 7.97 | 6 | 13.33 |
| Age > 55, Race = non-white ER+PR+HER2+ |
51 | 7.39 | 0 | 0 |
| Age > 55, Race = non-white ER+PR-/ER-PR+/ER-PR-HER2- |
30 | 4.34 | 0 | 0 |
| Age > 55, Race = non-white ER+PR-/ER-PR+/ER-PR-HER2+ |
25 | 3.62 | 0 | 0 |
| Age > 55, Race = non-white ER-PR-HER2- |
46 | 6.67 | 0 | 0 |
* The matching scheme delineated in the table allowed us to detect genes expressed differentially between the pre- and post-chemotherapy samples—genes that would not be confounded with the indicated demographic and clinical factors.